Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G. D’Addario, Daniel Betticher, Roger Stupp et al.|Annals of Oncology|2007Cited by 43